Marcus Pamela M, Freedman Andrew N, Khoury Muin J
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
Am J Prev Med. 2015 Nov;49(5):765-771. doi: 10.1016/j.amepre.2015.04.030. Epub 2015 Jul 10.
Targeted cancer screening refers to use of disease risk information to identify those most likely to benefit from screening. Researchers have begun to explore the possibility of refining screening regimens for average-risk individuals using genetic and non-genetic risk factors and previous screening experience. Average-risk individuals are those not known to be at substantially elevated risk, including those without known inherited predisposition, without comorbidities known to increase cancer risk, and without previous diagnosis of cancer or pre-cancer. In this paper, we describe the goals of targeted cancer screening in average-risk individuals, present factors on which cancer screening has been targeted, discuss inclusion of targeting in screening guidelines issued by major U.S. professional organizations, and present evidence to support or question such inclusion. Screening guidelines for average-risk individuals currently target age; smoking (lung cancer only); and, in some instances, race; family history of cancer; and previous negative screening history (cervical cancer only). No guidelines include common genomic polymorphisms. RCTs suggest that targeting certain ages and smoking histories reduces disease-specific cancer mortality, although some guidelines extend ages and smoking histories based on statistical modeling. Guidelines that are based on modestly elevated disease risk typically have either no or little evidence of an ability to affect a mortality benefit. In time, targeted cancer screening is likely to include genetic factors and past screening experience as well as non-genetic factors other than age, smoking, and race, but it is of utmost importance that clinical implementation be evidence-based.
靶向癌症筛查是指利用疾病风险信息来识别那些最有可能从筛查中获益的人群。研究人员已开始探索利用遗传和非遗传风险因素以及既往筛查经验来优化一般风险个体筛查方案的可能性。一般风险个体是指那些未被知晓存在显著升高风险的人群,包括那些没有已知遗传易感性、没有已知会增加癌症风险的合并症且没有既往癌症或癌前病变诊断的人群。在本文中,我们描述了一般风险个体靶向癌症筛查的目标,介绍了癌症筛查所针对的因素,讨论了美国主要专业组织发布的筛查指南中纳入靶向筛查的情况,并提供支持或质疑这种纳入的证据。目前,一般风险个体的筛查指南针对的是年龄;吸烟(仅针对肺癌);在某些情况下,还包括种族、癌症家族史以及既往阴性筛查史(仅针对宫颈癌)。没有指南纳入常见的基因多态性。随机对照试验表明,针对特定年龄和吸烟史进行筛查可降低特定疾病的癌症死亡率,尽管一些指南基于统计模型扩大了年龄范围和吸烟史标准。基于疾病风险适度升高制定的指南通常没有或几乎没有证据表明其有能力带来死亡率获益。随着时间的推移,靶向癌症筛查可能会纳入遗传因素、既往筛查经验以及年龄、吸烟和种族以外的其他非遗传因素,但至关重要的是临床实施要有循证依据。